Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Jerry Holubec

General Practice Keller, TX Doctor of Osteopathy

NPI 1831169895 CMS profile 264886

736 Hallelujah Trl, Keller, TX 76248

Open in the dashboard

General payments

$775

49 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jerry Holubec of Keller, TX is reported in the CMS Open Payments database as having received $775 across 49 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $19 1
2023 General $50 3
2022 General $111 7
2021 General $201 12
2020 General $352 23
2019 General $42 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jerry Holubec
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Jerry Holubec were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Jerry Holubec General Practice median Middle half National median
2019 $42 $107 $37–$285 $163
2020 $352 $75 $25–$213 $114
2021 $201 $93 $30–$272 $132
2022 $111 $103 $36–$279 $149
2023 $50 $106 $34–$276 $160
2024 $19 $114 $39–$290 $164
2025 $0 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Arbor Pharmaceuticals, Inc. $309 21 payments
  2. Medtronic USA, Inc. $126 10 payments
  3. Biohaven Pharmaceuticals, Inc. $69 4 payments
  4. Novartis Pharmaceuticals Corporation $49 2 payments
  5. RedHill Biopharma Inc. $44 2 payments
  6. CutisPharma, Inc. $32 2 payments
  7. Boston Scientific Corporation $29 2 payments
  8. AbbVie, Inc. $25 1 payment
  9. Averitas Pharma Inc. $23 1 payment
  10. Medtronic, Inc. $21 1 payment
  11. Other $48 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $775 49 payments
Products named General payments · program years 2019–2024
  1. Horizant Sleep $177 12 payments
  2. Horizant Sleep $133 9 payments
  3. INTELLIS Spinal Cord Neurostimulation $126 10 payments
  4. NURTEC ODT $90 5 payments
  5. AIMOVIG $49 2 payments
  6. Movantik $44 2 payments
  7. SPECTRA WAVEWRITER $29 2 payments
  8. UBRELVY $25 1 payment
  9. Qutenza $23 1 payment
  10. INTELLIS Spinal Cord Neurostimulation $21 1 payment
  11. Other $73 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

529

Median for Pain Management: 951

Drug cost

$13,733

Median for Pain Management: $26,034

Branded share of claims

39.3%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 162 $4,579
Morphine Sulfate Er Morphine Sulfate Brand 46 $2,023
Hydromorphone Hcl Generic 46 $1,903
Fentanyl Generic 17 $1,677
Gabapentin Generic 60 $1,025
Oxycodone Hcl Generic 46 $761
Methadone Hcl Generic 15 $596
Tizanidine Hcl Generic 41 $457
Methocarbamol Generic 29 $316
Promethazine Hcl Generic 18 $167

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$19,991

Medicare's payments for the services billed

Medicare patients

37

Average age 72

Services billed

570

21 women, 16 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 43%
Diabetes 32%
Depression 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
HORIZANT
  • CutisPharma, Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

49 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record